SpineGuard and Omnia Medical Strengthen Strategic Partnership for Sacroiliac Fusion Market Growth

SpineGuard (FR0011464452 – ALSGD) and Omnia Medical have announced the extension of their strategic partnership, marking a significant step in the growth of the sacroiliac fusion market. The collaboration between these innovative companies aims to make spine surgery safer, improve surgical outcomes, and reduce overall healthcare costs. By leveraging SpineGuard's proprietary DSG (Dynamic Surgical Guidance) sensing technology, the two companies are poised to revolutionize the placement of bone implants, particularly in the sacroiliac joint.

The initial agreement between SpineGuard and Omnia Medical, signed in September 2022, focused on two innovative devices: a drilling instrument for sacroiliac fusion and a smart pedicle screw system, both utilizing the DSG real-time, x-ray-free sensing technology. In September 2024, SpineGuard announced the FDA 510k clearance of its new PsiFGuard cannulated probe, designed to secure sacroiliac implant placement. Since then, numerous cases have been performed with the device, and the feedback from various physicians has been extremely positive. The PsiFGuard probe greatly facilitates the placement of Omnia's implant into the optimal position for success within the sacroiliac joint.

The two companies are working hand in hand on the preparation of the official market introduction of this combined product offering, scheduled for the end of January 2025 at the North American Neuromodulation Society (NANS) Annual Meeting in Orlando. This annual event brings together thousands of medical professionals in the spirit of innovation and collaboration, providing an ideal platform for the launch of this groundbreaking technology.

The sacroiliac fusion market is projected to grow at a 19% CAGR (compound annual growth rate) from 2022 to 2030, reaching over $539 million in 2021. This growth is driven by the increasing prevalence of degenerative sacroiliac joint conditions, which affect more than 15% of patients suffering from back pain. A new payment code implemented in the United States in January 2024 for sacroiliac joint fusion surgery is expected to accelerate this progression, further benefiting SpineGuard and Omnia Medical.

The expanded collaboration between SpineGuard and Omnia Medical includes the progressive extension of their collaboration to other products and countries, as well as the reallocation of SpineGuard resources to support Omnia's product launches, including PsiFGuard, in the United States. This strategic move will allow Omnia Medical to leverage the extensive experience and expertise of SpineGuard's personnel in the deployment of the DSG technology, which has been proven to secure and streamline the placement of bone implants in various surgical procedures.

By integrating SpineGuard's personnel into their team, Omnia Medical will be able to bring a consistently proven technology to new applications, such as the sacroiliac joint fusion, and expand its reach to more patients. The positive feedback received from physicians who have already used PsiFGuard during its limited release phase is a testament to the effectiveness of the DSG technology in facilitating the placement of implants in the sacroiliac joint. This success is likely to translate to other applications and geographies, as the technology has already demonstrated its multiple benefits in over 100,000 surgical procedures worldwide and has been validated by 34 studies published in peer-reviewed scientific journals.

In conclusion, the extension of the strategic partnership between SpineGuard and Omnia Medical is expected to contribute to the growth and success of both companies in the long term. By leveraging the expertise of SpineGuard's personnel and expanding the scope of their collaboration, the two companies will be able to bring innovative solutions to more patients, improve surgical outcomes, and reduce overall healthcare costs. The increasing prevalence of degenerative sacroiliac joint conditions and the new payment code for sacroiliac joint fusion surgery in the United States are further driving the growth of the sacroiliac fusion market, creating a favorable environment for the success of this strategic partnership.